- Home
- ARHS vs GHRS Comparison
ARHS vs GHRS Comparison
Compare ARHS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARHS | GHRS |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.8M | 947.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ARHS | GHRS |
|---|---|---|
| Price | $7.05 | $21.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $10.78 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 1.1M | 232.6K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $1,379,222,000.00 | N/A |
| Revenue This Year | $7.23 | N/A |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | ★ 8.51 | N/A |
| 52 Week Low | $6.17 | $9.52 |
| 52 Week High | $12.97 | $24.66 |
Technical Indicators
Market Signals| Indicator | ARHS | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 44.03 | 68.88 |
| Support Level | $6.17 | $12.54 |
| Resistance Level | $7.61 | $24.66 |
| Average True Range (ATR) | 0.34 | 1.67 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 14.06 | 62.73 |
Price Performance
Historical ComparisonAbout ARHS Arhaus Inc.
Arhaus Inc is a growing lifestyle brand and omnichannel retailer of premium home furniture. The company offers merchandise in several categories, including furniture, outdoor, lighting, textiles, and decor through its Retail and e-commerce sales channels.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.